Nanjing Leads Biolabs (HKG:9887) said Friday it has enrolled its first patient in China in a phase Ib/II study of a combination therapy involving its drug, LBL-024, to treat metastatic colorectal cancer (mCRC), according to a same-day bourse filing.
The company said the study is being led by Xu Ruihua of Sun Yat-sen University Cancer Center.
Shares were last up 2.6% in noon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments